Gamma Or Immune Patents (Class 424/85.5)
  • Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • Patent number: 10948497
    Abstract: A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with an intra-abdominal infection. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 16, 2021
    Assignee: The University of Pittsburgh—the Commonwealth of Higher Education
    Inventors: John A. Kellum, Zhiyun Cao, Derek Angus, Sachin Purushottam Yende, Rena Angilena Sowell Robinson
  • Patent number: 10857145
    Abstract: The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 8, 2020
    Assignee: DUKE UNIVERSITY
    Inventors: Nicole Calakos, Zachary F. Caffall, Joseph Rittiner
  • Patent number: 10857152
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: December 8, 2020
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, VIRACTA THERAPEUTICS, INC.
    Inventors: Ronald J. Berenson, Douglas V. Faller
  • Patent number: 10813908
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: October 27, 2020
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10800815
    Abstract: The present disclosure provides compounds that selectively bind and inhibit potassium channel Kv1.3.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: October 13, 2020
    Assignee: Select ION Therapeutics GMBH
    Inventors: Andreas Klostermann, Jörg Stockhaus
  • Patent number: 10729713
    Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis, liver fibrosis, and liver cancer, which comprises the following components in parts by weight: 0.15-10 parts of vinegar-baked bupleurum root polysaccharides or bupleurum root polysaccharides and 0.05-5 parts of a drug for treating hepatitis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: August 4, 2020
    Assignee: GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE
    Inventors: Ruizhi Zhao, Ya Zhao, Lijuan Liu
  • Patent number: 10632186
    Abstract: A novel method for preventing or treating an infectious disease in a subject in need thereof. In particular the method includes the administration of a combination, pharmaceutical combination, medicament or kit-of-parts having a first part including a CD8 vaccine specific for at least one infectious disease-related antigen, a second part including an agent neutralizing circulating alpha interferon and/or an agent blocking interferon alpha signaling, and/or a third part including a type III interferon and/or an agent stimulating the production of type III interferon.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: April 28, 2020
    Assignee: 21C Bio
    Inventor: Daniel Zagury
  • Patent number: 10624968
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 21, 2020
    Assignee: BICYCLERD LIMITED
    Inventors: Gavin Bennett, Daniel Paul Teufel
  • Patent number: 10508153
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: December 17, 2019
    Assignee: Amgen Fremont Inc.
    Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
  • Patent number: 10464882
    Abstract: The present invention discloses a Y-type discrete polyethylene glycol derivative, which has the advantages of determined molecular weights and the number of chain segments, and can avoid the defect of heterogeneity of a PEG derivative. In addition, the Y-type discrete polyethylene glycol derivative of the present invention may increase the water solubility of the discrete polyethylene glycol, and solve the problem of insufficient water solubility of the discrete polyethylene glycol-modified insoluble drug caused by an increase of the loading capacity.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: November 5, 2019
    Assignee: JENKEM TECHNOLOGY CO., LTD. (BEIJING)
    Inventors: Hui Zhu, Meina Lin, Xiaomeng Chen, Zhen'gang Zhu, Xuan Zhao
  • Patent number: 10413491
    Abstract: The present invention relates to a composition for the in vivo degradation of polysaccharide-containing fillers by radical degradation. The composition of the invention comprising at least one source of oxygen free radicals and at least one catalyst of oxygen free radical generation from the at least one source of oxygen free radicals. The present invention further relates to methods and uses of said composition for filler correction or reversal.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: September 17, 2019
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Lubin Belkovi, Franck Villain, Andreas Krause, Colin Drabe
  • Patent number: 10414816
    Abstract: The present invention relates to a method for purifying an immunoglobulin, and more particularly, to a method for purifying an immunoglobulin, which comprises: dissolving immunoglobulin-containing plasma protein fraction I+II+III or fraction II+III; adding caprylate to the solution to cause precipitation; performing dialysis and concentration after removal of the precipitate; performing anion exchange resin and ceramic cation exchange resin purification processes to effectively remove a solvent and detergent added to inactivate viruses; and performing elution while maintaining salt concentration at a constant level to maintain the immunoglobulin polymer content at a low level.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 17, 2019
    Assignee: GREEN CROSS HOLDINGS CORPORATION
    Inventors: Dong-Hwarn Park, Ki-Hwan Son, Kang Yun Seo, Sung Min Choi, Gun Sul Lee, Ki-Yong Kim
  • Patent number: 10336788
    Abstract: The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: July 2, 2019
    Assignee: MOERAE MATRIX, INC.
    Inventors: Cynthia Lander, Colleen Brophy, Cam Patterson
  • Patent number: 10273278
    Abstract: The present invention discloses a fragment of peptide which can be utilized in patients suffering from a disseminated mycobacterial infection. The fragment of peptide contains a sequence of amino acids with seven residues as formula (I) shown below, wherein X1 is Leucine (Leu); X2 is Proline (Pro); X3 is Glutamate (Glu); X4 is serine (Ser); X5 is Serine (Ser); X6 is Leucine (Leu) and X7 is Arginine (Arg): X1-X2-X3-X4-X5-X6-X7 (I).
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 30, 2019
    Assignee: CHANG GUNG UNIVERSITY
    Inventors: Cheng-Lun Ku, Chia-Hao Lin, Chih-Yu Chi, Han-Po Shih, Jing-Ya Ding
  • Patent number: 10208014
    Abstract: The invention relates to valproic acid derivatives or pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of valproic acid derivatives, and methods for treating or preventing neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: February 19, 2019
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9889180
    Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 13, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Qiang Yu, Zhen Ning Wee
  • Patent number: 9873671
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 23, 2018
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Patent number: 9862926
    Abstract: The present invention provides methods, kits, and compositions for reducing an innate immune system response in a human or animal cell, tissue or organism. One embodiment comprises: introducing an Agent mRNA comprising in vitro-synthesized mRNA encoding one or more proteins that affect the induction, activity or response of an innate immune response pathway; whereby, the innate immune response in the cell, tissue or organism is reduced compared to the innate immune response in the absence of the Agent mRNA. Other embodiments are methods, compositions and kits for using an Agent mRNA for treating a disease or medical condition in a human or animal that exhibits symptoms of an elevated innate immune system, or for reducing an innate immune response that is induced in a human or animal cell, tissue or organism by a Foreign Substance that is administered to the cell, tissue or organism.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: January 9, 2018
    Assignee: CellScript, LLC.
    Inventors: Cynthia Chin, Anthony D. Person, Gary A. Dahl
  • Patent number: 9763922
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 19, 2017
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Patent number: 9717648
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, daclizumab (ZENAPAX®).
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: August 1, 2017
    Assignee: Corning Incorporated
    Inventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 9707229
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 18, 2017
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 9572814
    Abstract: Methods of improving the pharmacokinetics of doxepin in a patient.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: February 21, 2017
    Assignee: Pernix Sleep, Inc.
    Inventors: Cara Baron Casseday, Elizabeth Ludington, Michael Skinner, Susan E. Dubé, Roberta L. Rogowski, Philip Jochelson, Robert Mansbach
  • Patent number: 9464128
    Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogs, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: October 11, 2016
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A.
    Inventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
  • Patent number: 9381230
    Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: July 5, 2016
    Assignee: BiOrion Technologies, B.V.
    Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
  • Patent number: 9302008
    Abstract: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 5, 2016
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 9249182
    Abstract: Disclosed herein are compositions and methods for purifying antibody products from a sample matrix. In particular, the present invention relates to compositions and methods for purifying antibody products employing hydrophobic interaction chromatography media. In certain embodiments, the invention provides a method for reducing process-related impurities (e.g., host cell proteins), as well as product-related substances, including molecular weight variants (e.g., aggregates and fragments of the antibody product).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 2, 2016
    Assignee: AbbVie, Inc.
    Inventors: Matthew Omon Herigstad, Linda E. Rich, Stephen Ming-teh Lu, Natarajan Ramasubramanyan
  • Patent number: 9248110
    Abstract: Compositions and methods for treating and preventing cancer, particularly lung cancer, lymphangioleiomyomatosis and asthma are provided.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 2, 2016
    Inventor: Steven Lehrer
  • Patent number: 9192621
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, RC and RD are as described herein.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: November 24, 2015
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa
  • Patent number: 9169212
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: October 27, 2015
    Assignee: Novira Therapeutics, Inc.
    Inventors: George D. Hartman, Scott Kuduk
  • Patent number: 9150636
    Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 6, 2015
    Assignee: Fox Chase Cancer Center
    Inventor: Kerry S. Campbell
  • Publication number: 20150132217
    Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
  • Publication number: 20150132258
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventor: George D. Hartman
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Publication number: 20150110736
    Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.
    Type: Application
    Filed: June 3, 2014
    Publication date: April 23, 2015
    Applicant: Nodality, Inc.
    Inventors: Wendy J. FANTL, Alessandra CESANO, Todd COVEY
  • Publication number: 20150098897
    Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicant: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu BRAHMBHATT, Jennifer MACDIARMID
  • Publication number: 20150079034
    Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.
    Type: Application
    Filed: June 13, 2014
    Publication date: March 19, 2015
    Inventors: Matthew SEAVEY, Yvonne Paterson, Paulo Maciag, Duane Sewell
  • Publication number: 20150079032
    Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: HASUMI INTERNATIONAL RESEARCH FOUNDATION
    Inventor: KENICHIRO HASUMI
  • Publication number: 20150079028
    Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.
    Type: Application
    Filed: August 5, 2013
    Publication date: March 19, 2015
    Applicant: SUNSHINE LAKE PHARMA CO., LTD
    Inventors: Yingjun Zhang, Jaincun Zhang, Hongming Xie, Qingyun Ren, Yumei Tan, Huichao Luo
  • Publication number: 20150080940
    Abstract: Described are embolization devices which carry M1 macrophage promoting agents and/or M2 macrophage inhibiting agents, as well as methods for their manufacture and use. An illustrative embolization device of the disclosure comprises an embolic body and one or more M1 macrophage promoting agents and/or M2 macrophage inhibiting agents carried by a surface of the embolic body. In certain embodiments the embolic body of the present disclosure comprises an embolic coil or an embolic bead.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 19, 2015
    Inventor: Colleen Gemborys
  • Publication number: 20150071992
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 12, 2015
    Inventors: DAVID C. CIPOLLA, JAMES BLANCHARD
  • Publication number: 20150064134
    Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Cynthia Lander, Colleen Brophy
  • Publication number: 20150064133
    Abstract: The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Erik J. Woods, Christopher Taylor
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20150056160
    Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
    Type: Application
    Filed: February 24, 2014
    Publication date: February 26, 2015
    Inventors: Nicholas Bachynsky, Woodie Roy
  • Publication number: 20150050237
    Abstract: The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 19, 2015
    Inventors: Vasu Nair, Maurice O. Okello, Machhindra G. Gund, Byung I. Seo, Pankajkumar R. Singh, Naveen K. Mangu
  • Publication number: 20150044165
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Application
    Filed: April 29, 2014
    Publication date: February 12, 2015
    Inventors: Lieping CHEN, Scott E. STROME, Eugene D. KWON
  • Publication number: 20150030564
    Abstract: An inhibitory agent for body cavity fluid accumulation exerts a drug efficacy on body cavity fluid accumulation that is resistant to administration of diuretics, and is capable of exerting therapeutic effects even by systemic administration. The inhibitory agent for body cavity fluid accumulation includes, as an active ingredient, a covalent conjugate of interferon with polyalkylene glycol.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 29, 2015
    Applicant: Toray Industries, Inc.
    Inventors: Hideki Narumi, Sanae Ikehara
  • Publication number: 20150023919
    Abstract: The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing nitric oxide, increasing suppressor CD8+ T cells and/or suppressing deleterious CD8+ and CD4+ T cells.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 22, 2015
    Inventors: Alexander Sasha Krupnick, Daniel Kreisel, Andrew Gelman
  • Publication number: 20150023920
    Abstract: The invention includes a method of preventing or treating metastasis in a subject diagnosed with cancer, the method comprising determining whether at least one gene encoding one or more proteins is upregulated in a cancer tissue sample from the subject as compared to the level of expression of the at least one gene in a non-cancer control sample of the same tissue, and, if the at least one gene is upregulated in the cancer tissue sample from the subject, administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more protein depleting agents.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 22, 2015
    Applicant: Drexel University
    Inventors: Alessandro Fatatis, Michael Russell, Qingxin (Cindy) Lui